#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15286	16S	1529	1529	99.93	16S.l6.c17.ctg.1	1963	767.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1659	1659	T	800	T,G	742,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15286	16S	1529	1529	99.93	16S.l6.c17.ctg.1	1963	767.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1393	1393	C	924	C,T	857,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15286	16S	1529	1529	99.93	16S.l6.c17.ctg.1	1963	767.7	0	HET	.	.	.	C712T,G	.	712	712	C	921	921	C	837	C,T,G	589,200,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15286	16S	1529	1529	99.93	16S.l6.c17.ctg.1	1963	767.7	0	HET	.	.	.	C790T,A	.	790	790	C	999	999	C	926	C,T,A	691,178,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28188	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3698	760.3	0	.	n	.	0	C543T	SNP	543	543	C	903	903	T	889	T,C	837,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28188	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3698	760.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1697	1697	A	972	A,G	899,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28188	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3698	760.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2331	2331	C	925	C	851	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28188	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3698	760.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2405	2405	A	863	A	814	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28188	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3698	760.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2957	2957	C	891	C,T	844,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28188	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3698	760.3	0	HET	.	.	.	C993T	.	993	993	C	1353	1353	C	848	C,T	650,141	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2074	folP	855	855	99.88	folP.l15.c4.ctg.1	1570	131.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1007	1009	AGC	202;201;204	A;G;C	188;186;187	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5112	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3386	150.3	0	.	p	.	0	V290I	NONSYN	868	870	GTT	1231	1233	ATT	151;153;150	A;T;T	144;146;145	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5112	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3386	150.3	1	SNP	p	S91F	0	.	.	271	273	TCC	634	636	TCC	174;175;175	T;C;C	163;165;165	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5112	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3386	150.3	1	SNP	p	D95G	0	.	.	283	285	GAC	646	648	GAC	168;163;165	G;A;C	162;156;158	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5112	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3386	150.3	1	SNP	p	D95N	0	.	.	283	285	GAC	646	648	GAC	168;163;165	G;A;C	162;156;158	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	1670	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1428	116.5	1	SNP	p	G45D	1	.	.	133	135	GAC	558	560	GAC	201;202;201	G;A;C	189;189;190	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	852	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1149	73.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4984	parC	2304	2304	99.7	parC.l6.c30.ctg.1	2827	175.1	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1556	1558	GCA	241;238;240	G,A;C,T;A	217,1;208,1;214	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4984	parC	2304	2304	99.7	parC.l6.c30.ctg.1	2827	175.1	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2039	2041	ATT	208;208;209	A;T;T	192;195;194	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4984	parC	2304	2304	99.7	parC.l6.c30.ctg.1	2827	175.1	1	SNP	p	D86N	0	.	.	256	258	GAC	509	511	GAC	166;166;169	G;A;C	161;157;163	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4984	parC	2304	2304	99.7	parC.l6.c30.ctg.1	2827	175.1	1	SNP	p	S87R	0	.	.	259	261	AGT	512	514	AGT	166;164;165	A;G;T	161;161;161	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4984	parC	2304	2304	99.7	parC.l6.c30.ctg.1	2827	175.1	1	SNP	p	S87I	0	.	.	259	261	AGT	512	514	AGT	166;164;165	A;G;T	161;161;161	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4984	parC	2304	2304	99.7	parC.l6.c30.ctg.1	2827	175.1	1	SNP	p	S87W	0	.	.	259	261	AGT	512	514	AGT	166;164;165	A;G;T	161;161;161	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4984	parC	2304	2304	99.7	parC.l6.c30.ctg.1	2827	175.1	1	SNP	p	S88P	0	.	.	262	264	TCC	515	517	TCC	165;164;163	T;C;C	157;158;159	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4544	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2553	176.9	0	.	p	.	0	H611N	NONSYN	1831	1833	CAC	2107	2109	AAC	197;197;199	A;A;C	180;169;187	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4544	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2553	176.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1504	1506	GGC	219;216;214	G,T;G;C	197,1;198;195	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	0	.	p	.	0	M35I	NONSYN	103	105	ATG	509	511	ATA	233;234;235	A;T;A	209;209;208	.	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	0	.	p	.	0	C41G	NONSYN	121	123	TGT	527	529	GGT	227;225;223	G;G;T,C	208;206;203,1	.	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	0	.	p	.	0	A70T	NONSYN	208	210	GCA	614	616	ACA	246;245;242	A,G;C;A	230,1;232;230	.	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	0	.	p	.	0	D101E	NONSYN	301	303	GAT	707	709	GAG	210;207;207	G;A;G	203;199;199	.	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	0	.	p	.	0	Y201H	NONSYN	601	603	TAT	1007	1009	CAT	220;217;214	C,T;A,G;T	209,1;208,1;207	.	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	0	.	p	.	0	Q230K	NONSYN	688	690	CAA	1094	1096	AAA	236;233;233	A;A;A	217;221;220	.	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	0	.	p	.	0	L447V	NONSYN	1339	1341	CTC	1745	1747	GTC	232;231;235	G,C;T;C	213,1;209;211	.	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	0	.	p	.	0	V515I	NONSYN	1543	1545	GTC	1949	1951	ATC	231;231;230	A;T,A;C	209;206,1;212	.	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1337	1339	GCA	222;226;226	G;C;A	204;206;210	penA.0.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1340	1342	ATC	223;224;226	A;T;C	211;208;208	penA.0.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1352	1354	GTG	218;219;221	G;T;G	204;204;208	penA.0.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1352	1354	GTG	218;219;221	G;T;G	204;204;208	penA.0.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1853	1855	ACC	213;212;212	A;C;C,A	190;195;195,1	penA.0.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1907	1909	GCG	219;217;214	G;C;G,A	178;169;166,1	penA.0.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1907	1909	GCG	219;217;214	G;C;G,A	178;169;166,1	penA.0.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2039	2041	GGC	173;169;166	G;G;C	161;158;150	penA.0.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	4258	penA	1746	1746	98.17	penA.l6.c4.ctg.1	2426	174.5	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2057	2059	CCG	163;167;163	C,G;C;G	128,3;131;128	penA.0.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5932	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3072	192.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2174	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1823	118.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	526	526	C	166	C,A	150,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2956	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1423	203.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	682	684	GGA	204;205;206	G,A;G;A	187,1;188;185	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2956	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1423	203.0	0	.	p	.	0	.	INDELS	629	630	AA	885	887	TAG	227;228;225	T;A;G	215;218;211	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2956	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1423	203.0	0	.	p	.	0	.	MULTIPLE	631	633	TAC	889	892	CAAT	229;230;234;237	C;A;A;T	219;219;224;226	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2956	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1423	203.0	0	.	p	.	0	N212fs	FSHIFT	634	634	A	894	894	T	241	T	228	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2956	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1423	203.0	1	SNP	p	G120K	0	.	.	358	360	GGT	613	615	GGT	221;218;219	G;G;T	207;206;204	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2956	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1423	203.0	1	SNP	p	A121D	0	.	.	361	363	GCC	616	618	GCC	220;219;221	G;C,G;C	206;206,1;211	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2956	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1423	203.0	1	SNP	p	A121N	0	.	.	361	363	GCC	616	618	GCC	220;219;221	G;C,G;C	206;206,1;211	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11242	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4823	232.3	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1990	1992	CAT	227;227;227	C;A;T	211;210;211	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1218	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	978	122.7	1	SNP	p	V57M	0	.	.	169	171	GTG	503	505	GTG	256;255;254	G,A;T;G,T	237,1;239;239,1	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
